Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 58

Results For "ABLE"

5843 News Found

Fresenius Kabi & TQ Therapeutics join forces to accelerate cell & gene therapy manufacturing
News | January 21, 2026

Fresenius Kabi & TQ Therapeutics join forces to accelerate cell & gene therapy manufacturing

The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing


Medico Remedies secures government supply order of Rs. 73.23 Cr
News | January 21, 2026

Medico Remedies secures government supply order of Rs. 73.23 Cr

Medico Remedies has secured the order to supply Azithromycin 500gm (tablets) to Uttar Pradesh Medical Supplies Corporation Limited


Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy
News | January 21, 2026

Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy

The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026


Lupin and Galenicum ink license and supply agreement for semaglutide in 23 countries
News | January 21, 2026

Lupin and Galenicum ink license and supply agreement for semaglutide in 23 countries

Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally


FDA go ahead for Eli Lilly’s therapy for hard-to-treat ovarian cancer
Drug Approval | January 21, 2026

FDA go ahead for Eli Lilly’s therapy for hard-to-treat ovarian cancer

Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells


AstraZeneca to withdraw Nasdaq listings ahead of NYSE direct listing
News | January 21, 2026

AstraZeneca to withdraw Nasdaq listings ahead of NYSE direct listing

The move follows AstraZeneca’s previously announced plan to complete a direct listing of its Ordinary Shares and debt securities on the New York Stock Exchange


Sigachi Industries achieves key R&D milestone in Cystic Fibrosis APIs
R&D | January 21, 2026

Sigachi Industries achieves key R&D milestone in Cystic Fibrosis APIs

The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments


China nod to first homegrown BNCT cancer drug for human trials
R&D | January 20, 2026

China nod to first homegrown BNCT cancer drug for human trials

The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials


DNA Nanorobots & AI could slash drug development times, Nanovery CEO says
Biotech | January 20, 2026

DNA Nanorobots & AI could slash drug development times, Nanovery CEO says

DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours